Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2002

View Archived Issues

Microscience advances oral typhoid vaccine into U.S. clinical trials

BioMS acquires new platform technology for hematopoietic cell mobilization

Novel small-molecule leads targeting the V2 vasopressin receptor

New data on nesiritide discussed at 2002 HFSA meeting

OSI-211 enters phase II trials in ovarian and small cell lung cancers

Polydex updates progress of Ushercell

Beneficial effects on memory reported for selective cannabinoid antagonist

BioFocus and Axxima form drug discovery partnership

Celera Genomics purchases rights to preclinical asthma compounds from Bayer

Pozen submits MT-100 MAA in U.K.

Celltech patent describes novel agents for TNF-alpha-mediated disorders

Novel tryptase inhibitors covered by Boehringer Ingelheim patent

New MMP-2 and/or MMP-13 inhibitors identified at Pharmacia

Protein kinase inhibitors described by Pharmacia as useful for cancer and other disorders

4SC and Schering AG form research collaboration

Novel antibacterial thiazolidinediones in GSK development pipeline

Multiple-dose OxyTrex and MorViva studies completed

U. of Kentucky researchers present novel camptothecin prodrugs

Phosphonate nucleotide and its oral prodrug with potent, selective anti-HBV activity

Dutasteride approved for launch as first dual-acting 5alpha-reductase inhibitor for BPH

Resovist cleared for marketing in Japan for early detection of liver tumors

Angiomax receives clearance in Canada

Broad-spectrum antiepileptic effects demonstrated for AMP-397A

Mechanism of action of plant-derived antiepileptic agent discussed by Mexican group in Madrid

Additional reduction in LDL cholesterol levels with coadministration of ezetimibe and simvastatin

The proteasome inhibitor PS-519 is safe and well tolerated in healthy volunteers

Potential use of leflunomide in psoriasis and psoriatic arthritis

Pipeline on the Move - Neurologic drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...